Loading...
Docoh

Medtronic (MDT)

Medtronic plc, headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Company profile

Ticker
MDT
Exchange
CEO
Geoffrey Martha
Employees
Location
Fiscal year end
Former names
Medtronic Holdings Ltd, Medtronic Ltd
SEC CIK
Subsidiaries
2074417 Alberta ULC • A&E Products de Honduras S.A. • A&E Products do Brasil Ltda. • A&E Products Group, Inc. • Advanced Medical Technologies GmbH • AI Biomed Corp • Aircraft Medical Ltd. • Airox, Inc. • Arterial Vascular Engineering Canada, Company • Arterial Vascular Engineering UK Limited ...

MDT stock data

Calendar

1 Sep 22
25 Sep 22
28 Apr 23
Quarter (USD) Jul 22 Apr 22 Jan 22 Oct 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Apr 22 Apr 21 Apr 20 Apr 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 2.14B 2.14B 2.14B 2.14B 2.14B 2.14B
Cash burn (monthly) 524.67M 72M (no burn) (no burn) (no burn) (no burn)
Cash used (since last report) 989.89M 135.84M n/a n/a n/a n/a
Cash remaining 1.15B 2B n/a n/a n/a n/a
Runway (months of cash) 2.2 27.8 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Aug 22 Geoffrey Martha Ordinary Shares Grant Acquire A No No 0 28,471 0 102,497
1 Aug 22 Geoffrey Martha Stock Option Ordinary Shares Grant Acquire A No No 93.08 224,996 20.94M 224,996
1 Aug 22 Geoffrey Martha Performance Share Units Performance Share Units Grant Acquire A No No 0 71,176 0 71,176
1 Aug 22 Parkhill Karen L Ordinary Shares Grant Acquire A No No 0 10,744 0 30,962
1 Aug 22 Parkhill Karen L Stock Option Ordinary Shares Grant Acquire A No No 93.08 84,905 7.9M 84,905
1 Aug 22 Parkhill Karen L Performance Share Units Performance Share Units Grant Acquire A No No 0 26,859 0 26,859
1 Aug 22 Robert John White Ordinary Shares Grant Acquire A No No 0 8,595 0 36,351
1 Aug 22 Robert John White Stock Option Ordinary Shares Grant Acquire A No No 93.08 67,924 6.32M 67,924
1 Aug 22 Robert John White Performance Share Units Performance Share Units Grant Acquire A No No 0 21,487 0 21,487
1 Aug 22 Ivan K Fong Ordinary Shares Grant Acquire A No No 0 6,941 0 37,722
13F holders Current Prev Q Change
Total holders 1889 1964 -3.8%
Opened positions 114 197 -42.1%
Closed positions 189 161 +17.4%
Increased positions 802 927 -13.5%
Reduced positions 739 633 +16.7%
13F shares Current Prev Q Change
Total value 93.81B 131.2B -28.5%
Total shares 1.04B 1.05B -1.0%
Total puts 4.48M 4.82M -7.0%
Total calls 6.98M 8.06M -13.4%
Total put/call ratio 0.6 0.6 +7.4%
Largest owners Shares Value Change
Vanguard 122.8M $11.02B +1.9%
BLK Blackrock 110.38M $9.91B +2.2%
STT State Street 58.06M $5.25B -0.8%
Massachusetts Financial Services 37.46M $3.36B -9.3%
Wellington Management 32.63M $2.93B +4.9%
BAC Bank Of America 26.88M $2.41B +4.3%
Geode Capital Management 26.53M $2.38B +3.8%
Capital Research Global Investors 26.04M $2.34B +18.2%
BEN Franklin Resources 24.87M $2.23B -0.5%
MS Morgan Stanley 17.49M $1.57B +16.9%
Largest transactions Shares Bought/sold Change
TROW T. Rowe Price 11.43M -7.84M -40.7%
Lazard Asset Management 16.15M -5.91M -26.8%
AMP Ameriprise Financial 9.48M -5.06M -34.8%
Parametric Portfolio Associates 0 -4.91M EXIT
BCS Barclays 10.08M +4.27M +73.5%
Capital Research Global Investors 26.04M +4.01M +18.2%
Massachusetts Financial Services 37.46M -3.85M -9.3%
MS Morgan Stanley 17.49M +2.53M +16.9%
Arrowstreet Capital, Limited Partnership 3.77M +2.47M +189.3%
BLK Blackrock 110.38M +2.39M +2.2%

Financial report summary

?
Risks
  • We operate in a highly competitive industry and we may be unable to compete effectively.
  • The ongoing global COVID-19 pandemic has had, and may continue to have, an adverse effect on certain aspects of our business, results of operations, financial condition and cash flows. The nature and extent of future impacts are highly uncertain and unpredictable.
  • Reduction or interruption in supply or other manufacturing difficulties may adversely affect our manufacturing operations and related product sales.
  • Our research and development efforts rely upon investments and investment collaborations, and we cannot guarantee that any previous or future investments or investment collaborations will be successful.
  • The continuing development of many of our products depends upon us maintaining strong relationships with healthcare professionals.
  • We have debt obligations that create risk.
  • Failure to integrate acquired businesses into our operations successfully, as well as liabilities or claims relating to such acquired businesses, could adversely affect our business.
  • We are subject to extensive and complex laws and governmental regulations and any adverse regulatory action may materially adversely affect our financial condition and business operations.
  • Our failure to comply with laws and regulations relating to reimbursement of healthcare goods and services may subject us to penalties and adversely impact our reputation, business, results of operations, financial condition and cash flows.
  • We are substantially dependent on patent and other proprietary rights and failing to protect such rights or to be successful in litigation related to our rights or the rights of others may result in our payment of significant monetary damages and/or royalty payments, negatively impacting our ability to sell current or future products.
  • Quality problems could lead to recalls or safety alerts, product liability claims, reputational harm, adverse verdicts or costly settlements, and could have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • Healthcare policy changes may have a material adverse effect on us.
  • We rely on the proper function, security and availability of our information technology systems and data, as well as those of third parties throughout our global supply chain, to operate our business, and a breach, cyber-attack or other disruption to these systems or data could materially and adversely affect our business, results of operations, financial condition, cash flows, reputation or competitive position.
  • The failure to comply with anti-corruption laws could materially adversely affect our business and result in civil and/or criminal sanctions.
  • Laws and regulations governing international business operations could adversely impact our business.
  • Climate change, or legal, regulatory or market measures to address climate change may materially adversely affect our financial condition and business operations.
  • We are subject to environmental laws and regulations and the risk of environmental liabilities, violations and litigation.
  • Our insurance program may not be adequate to cover future losses.
  • Changes in tax laws or exposure to additional income tax liabilities could have a material impact on our business, results of operations, financial condition and cash flows.
  • The Medtronic, Inc. tax court proceeding outcome could have a material adverse impact on our financial condition.
  • Future potential changes to the U.S. tax laws could result in us being treated as a U.S. corporation for U.S. federal tax purposes, and the IRS may not agree with the conclusion that we should be treated as a foreign corporation for U.S federal income tax purposes.
  • Legislative or other governmental action relating to the denial of U.S. federal or state governmental contracts to U.S. companies that redomicile abroad could adversely affect our business.
  • We are incorporated in Ireland, and Irish law differs from the laws in effect in the U.S. and may afford less protection to holders of our securities.
  • As an Irish public limited company, certain capital structure decisions require shareholder approval, which may limit Medtronic’s flexibility to manage its capital structure.
  • A transfer of our shares, other than ones effected by means of the transfer of book-entry interests in the Depository Trust Company, may be subject to Irish stamp duty.
  • In certain limited circumstances, dividends we pay may be subject to Irish dividend withholding tax and dividends received by Irish residents and certain other shareholders may be subject to Irish income tax.
  • Our shares received by means of a gift or inheritance could be subject to Irish capital acquisitions tax.
  • Changes in the prices of our goods and services and/or inflationary costs may have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • We are subject to a variety of risks associated with global operations that could adversely affect our profitability and operating results.
  • Consolidation in the healthcare industry could have an adverse effect on our revenues and results of operations.
  • Healthcare industry cost-containment measures could result in reduced sales of our medical devices and medical device components.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: AdaptivCRT, addressing, adult, armed, artificial, backlog, bariatric, bear, calendar, carryover, contemplated, contrast, coordinated, COVID, CRS, customary, DaVita, Defibrillation, discover, dropped, easier, economy, expedited, Fong, freight, fuel, half, Ivan, kidney, leader, mapping, Minnesota, Multidistrict, neonatal, NewCo, ownership, Oxysoft, packaging, parallel, portion, President, procurement, reiterated, release, SAVR, scenario, standalone, suffer, suite, technical, TriageHF, VBP, Vice
Removed: accelerate, acquire, adjust, administer, administered, AF, affiliate, annually, application, Argentina, authorization, automating, awaiting, bicuspid, Bluetooth, breathe, carried, cleared, Companion, confirm, Cyber, decade, deep, Delta, designation, disclose, discount, discounted, double, downturn, Dr, EffectivCRT, effectively, embolic, encryption, esophageal, exceeded, execution, exercised, expensing, experiencing, expressly, extra, favorable, February, floating, FSB, fully, functionality, GL, highly, impaired, implemented, import, imported, incident, Indiana, Intrepid, intuitive, jury, labeling, liquid, List, mitral, mobile, model, Modulation, month, moving, NaN, negative, notification, notwithstanding, NPWMD, obtaining, OFAC, offered, offering, Office, opening, ordinarily, originally, overhead, patent, precaution, predictable, preferred, progressive, ranging, realigned, realignment, recoverable, repaid, repay, respectfully, Restorative, retained, returned, reusable, Rex, ruling, Russia, Russian, Sasso, SDN, settled, slowdown, specifically, spherical, stage, supported, tag, terminal, terminated, trade, treated, tricuspid, unapproved, unprecedented, updated, utilizing, variant, verdict, WACC, week